Category: ALK Positive News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
First Patient Dosed in Tri-611 Clinical Trial
The first patient has been dosed in the Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive NSCLC, marking an important step forward in the development of new investigational therapies for the ALK-positive community.
-
Nuvalent Announces Submission of New Drug Application to the FDA for Neladalkib (NVL-655) in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent has officially filed for FDA approval of NVL-655 (neladalkib), a promising next-generation ALK inhibitor for previously treated ALK-positive lung cancer. Backed by results from the ongoing ALKOVE-1 trial, this milestone could bring a powerful new treatment option one step closer for patients facing progression after prior ALK therapies.
-
Honoring a Legacy: The John Pender Scholarship Fund
The John Pender Scholarship Fund, established in 2025, honors John’s legacy by supporting students connected to the ALK-positive community who are pursuing higher education. Each year, the scholarship helps a student working toward a future rooted in service, creativity, innovation, or care for others. The inaugural award supported a student pursuing nursing, continuing John’s spirit…
-
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research
ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…
-
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer
We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer. This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences. Funding is available for organizations…
-
ALK Positive and the American Association for Cancer Research (AACR) partner to fund a two-year AACR-ALK Positive Lung Cancer Research Fellowship
ALK Positive Partners with AACR to Advance ALK-Positive Lung Cancer Research ALK Positive has partnered with the American Association for Cancer Research (AACR) to fund a two-year AACR–ALK Positive Lung Cancer Research Fellowship supporting early-career investigators in ALK-positive lung cancer research. The 2025 awardee, Alice Tzeng, MD, PhD of Dana-Farber Cancer Institute, is studying epigenetic…
-
ALK Positive Inc. Appoints Dr. Ken Culver as Executive Director & Medical Director to Lead Research and Patient Advocacy Initiatives
ALK Positive has appointed Dr. Ken Culver as Executive Director and Medical Director to guide the organization’s strategy and research investments. A physician-scientist with expertise in oncology and drug development, Dr. Culver has advanced patient-driven science and global collaborations since joining ALK Positive in 2022. His leadership marks an exciting new chapter in accelerating research…
-
Participate in Survey to Help our Medical Committee
The ALK Positive Inc. Medical Committee is seeking patient and caregiver input to enhance DDI Manager — an online resource that helps identify potential drug–drug interactions between cancer treatments and other medications. Your feedback can make a real difference in improving this tool for the entire ALK+ community. Participation takes just 10–15 minutes.
-
Takeda Oncology Co-Pay Assistance Progam
As of October 1, 2025, ALUNBRIG® (brigatinib) is now covered at Cigna Healthcare, giving most commercial patients faster access and lower out-of-pocket costs. With this update, about 99% of commercial lives are covered for ALUNBRIG. Learn more about co-pay assistance at takedaoncologycopay.com .
-
Managing Lorlatinib Together: What Patients and Experts Want You to Know
“Patients can—and should—have a voice in their care. This guide is about giving them the tools to do just that.” — Nancee Pronsati, ALK Positive Inc.
-
ALK Positive Announces Formation of Distinguished Scientific Advisory Board
ALK Positive, in collaboration with 23andMe Holding Co., a leading genetic health and biopharmaceutical company, and 20 lung cancer advocacy organizations, today announces a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to…
-
MEET YOUR STAFF: Introducing Sadia Yaakov, Medical Project Manager at ALK Positive, Inc
I was born and raised in Pennsylvania and had an interest in cancer research from the time that I was a child. I was exposed to Fox Chase Cancer Center very early on and knew from that moment that I wanted to do something to help in the fight against cancer. I attended University of…